Hologic (NASDAQ:HOLX)‘s stock had its “buy” rating reissued by equities researchers at Piper Jaffray Companies in a research report issued to clients and investors on Thursday, November 9th. They currently have a $48.00 price target on the medical equipment provider’s stock. Piper Jaffray Companies’ price target points to a potential upside of 18.67% from the company’s previous close.
HOLX has been the subject of several other reports. Royal Bank Of Canada reduced their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Thursday, August 3rd. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Barclays dropped their price target on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and a consensus target price of $47.54.
Shares of Hologic (HOLX) opened at $40.45 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. The company has a market capitalization of $11,150.00, a PE ratio of 20.23, a PEG ratio of 1.98 and a beta of 0.93. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80.
In other news, Director Lawrence M. Levy sold 7,138 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 1,256 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the transaction, the vice president now owns 9,406 shares of the company’s stock, valued at $369,561.74. The disclosure for this sale can be found here. Insiders sold a total of 35,972 shares of company stock valued at $1,385,977 over the last quarter. 0.79% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Hologic during the 3rd quarter valued at $618,000. GSA Capital Partners LLP grew its position in shares of Hologic by 379.5% during the 3rd quarter. GSA Capital Partners LLP now owns 63,760 shares of the medical equipment provider’s stock valued at $2,339,000 after purchasing an additional 50,463 shares in the last quarter. Americafirst Capital Management LLC purchased a new position in shares of Hologic during the 3rd quarter valued at $554,000. IFM Investors Pty Ltd purchased a new position in shares of Hologic during the 3rd quarter valued at $335,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in shares of Hologic by 66.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock valued at $458,000 after purchasing an additional 4,984 shares in the last quarter. Hedge funds and other institutional investors own 93.80% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.